Business Context and Reporting Period
This Form 8-K filing by IDEAYA Biosciences, Inc. (IDYA) reports a current event dated January 4, 2024, with the report signed on January 12, 2024. The filing details the execution of an at-the-market (ATM) equity offering under a pre-existing sales agreement.
Key Financial Metrics
The filing discloses specific capital raising activity but does not provide comprehensive financial statements such as revenue, profit, or operating cash flow.
- Shares Sold: 4,553,781 shares of common stock.
- Net Proceeds: Approximately $158.9 million.
- Weighted Average Sales Price: Approximately $35.97 per share.
- Remaining ATM Capacity: Approximately $58.7 million available as of January 12, 2024.
- Original ATM Facility Size: Up to $250.0 million (established June 26, 2023).
Material Changes
The primary material change is the reduction of the available equity under the June 2023 Open Market Sales Agreement with Jefferies LLC. The company utilized a significant portion of the facility to raise capital, leaving approximately $58.7 million of the original $250.0 million authorization remaining.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity sale. The transaction was executed at the company's sole discretion under the terms of the existing sales agreement.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the intended use of the $158.9 million in net proceeds (e.g., clinical trials, general corporate purposes).
- Monitor the remaining $58.7 million ATM facility for potential future sales.
- Review the company's most recent 10-Q or 10-K for baseline liquidity and cash position prior to this infusion.